Interleukin 35: An overview
More details
Hide details
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Department of Obstetrics, Perinatology and Gynecology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2019-12-26
Final revision date: 2020-06-18
Acceptance date: 2020-07-10
Online publication date: 2020-10-31
Corresponding author
Natalia Zdanowska   

Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Wojska Polskiego 30, 10-229 Olsztyn, Poland. Tel.: +48 502 232 591.
Pol. Ann. Med. 2020;27(2):225-229
Interleukin 35 (IL-35) has recently been characterized as a cytokine connected with the IL-12 group. The secretion of IL-35 was described in forkhead box protein 3 (Foxp3) + regulatory T cells (Tregs), peripheral γδ T cells, CD8+ T cells, placental trophoblasts, antigen-presenting cells (APCs) and regulatory B cells (Breg).

The aim of this paper is to systematize current knowledge about IL-35 production and discuss its impact on the pathophysiology and outcome of various diseases.

Material and methods:
Literature review was conducted.

Results and discussion:
IL-35 plays a pivotal role in the immune dysregulation in the pathogenesis of cardiovascular diseases including atherosclerosis, psychiatric and neurologic disorders, cancer, allergic and autoimmune diseases and psoriasis, inducing the expression of Treg-related cytokines and inhibiting the expression of Th1- and Th17-related cytokines.

None declared.
None declared.
Su LC, Liu XY, Huang AF, Xu WD. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmun Rev. 2018;17(7):665–673.
Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family?. Immunol Rev. 2008;226:248–262.
Huang A, Cheng L, He M, Nie J, Wang J, Jiang K. Interleukin-35 on B cell and T cell induction and regulation. J Inflamm (Lond). 2017;14:16.
Yazdani Z, Rafiei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL-35, a double-edged sword in cancer. J Cell Biochem. 2020;121(3):2064–2076.
Dambuza IM, He C, Choi JK, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. Nat Commun. 2017;8(1):719.
Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-inflammatory cytokine – a new system of categorizing anti-inflammatory cytokines. PLoS One. 2012;7(3):e33628.
Wang Y, Mao Y, Zhang J, et al. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med. 2018;22(2):1014–1025.
Fogel O, Rivière E, Seror R, et al. Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. J Allergy Clin Immunol. 2018;142(1):258–268.e5.
Zhu Z, Zhang Y, Ye J, et al. IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases. Hum Immunol. 2018;79(12):869–875.
Zhang J, Zhang Y, Wang Q, et al. Interleukin-35 in immune-related diseases: protection or destruction. Immunology. 2019;157(1):13–20.
Li Y, Wang Y, Liu H, et al. Lower level of IL35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs testpositive hemocytopenia. Mol Med Rep. 2018;17(2):2973–2981.
Guo J, Gu M, Zhang W, Liu Y, Qian C, Deng A. Aberrant IL-35 levels in patients with primary Sjogren’s syndrome. Scand J Immunol. 2018;88(5):e12718.
Espes D, Singh K, Sandler S, Carlsson PO. Increased interleukin-35 levels in patients with type 1 diabetes with remaining C-peptide. Diabetes Care. 2017;40(8):1090–1095.
Ye Z, Jiang Y, Sun D, Zhong W, Zhao L, Jiang Z. The plasma interleukin (IL)-35 level and frequency of circulating IL-35+ regulatory B cells are decreased in a cohort of Chinese patients with new-onset Systemic Lupus erythematosus. Sci Rep. 2019;9(1):13210.
Li Y, Yao L, Liu S, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. J Investig Med. 2019;67(3):707–710.
Chen C, Deng Y, Chen H, et al. Decreased concentration of IL-35 in plasma of patients with asthma and COPD. Asian Pac J Allergy Immunol. 2014;32(3):211–217.
Zeng JC, Zhang Z, Li TY, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6(9):1806–1816.
Jiang Q, Li Y, Xia L, Shen H, Lu J. Interleukin-35: A serological biomarker for patients with polymyositis/dermatomyositis. J Interferon Cytokine Res. 2019;39(11):720–725.
Huang C, Li N, Li Z, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun. 2017;8:14035.
Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 dampens CD8+ T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma. Front Immunol. 2019;10:1032.
Heim L, Kachler K, Siegmund R, et al. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer. Br J Cancer. 2019;120(9):903–912.
El-Gendy SG, El-Sabaa EM, El-Feky MA, Ahmed SH, Eid SS. Plasma levels of interleukin-35 and its association with clinical features of breast cancer patients at Assiut University Hospitals. Egypt J Immunol. 2019;26(1):121–128.
Fan YG, Zhai JM, Wang W, et al. IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev. 2015;16(7):2845–2849.
Wang J, Tao Q, Wang H, et al. Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia. Hum Immunol. 2015;76(9):681–686.
Akcali A, Zengin F, Aksoy SN, Zengin O. Fatigue in multiple sclerosis: Is it related to cytokines and hypothalamic-pituitary-adrenal axis?. Mult Scler Relat Disord. 2017;15:37–41.
Dantas AT, Gonçalves SM, Pereira MC, et al. Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement. Clin Rheumatol. 2015;34(9):1621–1625.
Suzuki M, Yokota M, Nakamura Y, Ozaki S, Murakami S. Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis. Allergol Int. 2017;66(2):351–356.
Li T, Gu M, Liu P, et al. Clinical significance of decreased interleukin-35 expression in patients with psoriasis. Microbiol Immunol. 2018.
Mavropoulos A, Varna A, Zafiriou E, et al. IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells. Clin Immunol. 2017;184:33–41.
Georgescu SR, Tampa M, Caruntu C, et al. Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 2019;20(3):739.
Zhang J, Lin Y, Li C, et al. Correction: IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis. J Immunol. 2020;204(11):3056–3057.
Rose D, Ashwood P. Rapid communication: Plasma interleukin-35 in children with autism. Brain Sci. 2019;9(7):152.
33 Badihian S, Shaygannejad V, Soleimani P, et al. Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progression. J Biol Regul Homeost Agents. 2018;32(5):1249–1253.
Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S. Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep. 2016;6:25886.
Zhang LJ, Guo HY, Zhang DQ, et al. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome. Clin Chim Acta. 2017;468:5–9.
Sonmez C, Yucel AA, Yesil TH, et al. Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet’s patients. Clin Rheumatol. 2018;37(10):2797–2804.
Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer. 2018;143(9):2105–2115.
Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–370.
Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4+CD25+CD127dim/- regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J. 2019;16(1):48.
Journals System - logo
Scroll to top